View Older Stories
-
Biogen (BIIB) Stock Falls on Alzheimer's Drug Trial Death Reports
-
Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm
-
RBC Capital Upgrades Biogen (BIIB) to Outperform
-
Biogen (BIIB) Gains as CEO Hints at 'Strategic Options'
-
Biogen's Alzheimer's drug gets negative European panel vote
-
Ionis Pharmaceuticals (IONS) is High Risk but RBC Capital Likes the Setup Into ALS Data
-
Biogen (BIIB) Analyst Day Offered Little Incremental Value - RBC Capital
-
UPDATE: Biogen (BIIB) PT Lowered to $354 at RBC Capital
-
Prothena Corp (PRTA) PT Raised to $50 at RBC Capital
-
UPDATE: Biogen (BIIB) PT Raised to $256 at RBC Capital After SAGE Deal Call
-
Biogen (BIIB) PT Lowered to $268 at RBC Capital After Mock Adcomm
-
Biogen's (BIIB) Tecfidera Drop-off Will Be Larger than Expected, PT Lowered to $277 - RBC Capital
-
Biogen (BIIB) Tecfidera Reduction Impact ~$20/Share - RBC
-
Pre-Open Stock Movers 06/18: (ALPN) (AEMD) (ELOX) Higher; (LPTX) (QUIK) (BIIB) Lower (more...)
-
Biogen (BIIB) PT Lowered to $303 at RBC Capital Ahead of District Court Rulings
-
Biogen (BIIB) PT Raised to $321 at RBC Capital
-
Biogen (BIIB) PT Lowered to $280 at RBC Capital
-
RBC Capital Remains on Biogen (BIIB) Sidelines Ahead of PTAB IPR Decision
-
Biogen (BIIB) New 'Mystery' Candidate BIIB101 Moves Into Clinic - RBC
-
Biogen, Eisai revive plans for Alzheimer's drug, surprising market
-
Biogen (BIIB) News 'Somewhat Astonishing', Shares Could Trade Back Toward Low-$300s - RBC
-
Biogen (BIIB) BG00011 Just Stopped For Toxicity, But Low Impact - RBC
-
Biogen (BIIB) Competitor Likely to Post Pivotal Results Next Week - RBC Capital
-
Biogen (BIIB) PT Raised to $242 at RBC Capital
-
Biogen (BIIB) PT Lowered to $234 at RBC Capital
-
Biogen (BIIB) PT Slashed At RBC On Alzheimer's Prospects
-
Complex Setup Keeps RBC on Sidelines with Biogen (BIIB); PT Lowered to $318
-
Biogen (BIIB) PT Lowered to $337 at RBC Capital
-
Bristol-Myers/Celgene Deal Likely Kicks Off 'Big Year' In Biopharma M&A - RBC
-
Biogen (BIIB) PT Lowered to $338 at RBC Capital on Underappreciated Tecfidera IP Risk
-
Biogen (BIIB) PT Raised to $364 at RBC Capital
-
Biogen (BIIB) PT Raised to $357 at RBC Capital
-
Biogen (BIIB): Positive Alzheimer's Data Likely A Big Catalyst - RBC
-
RBC Positive on Biogen (BIIB) Karp Hire Amid Partnerships/M&A Potential
-
RBC Sees Positive Read-Through to Alder Biopharm (ALDR) from Allergan, Biogen Developments
-
Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies - RBC
-
Biogen (BIIB) PT Lowered to $311 at RBC Capital
-
Biogen (BIIB) Missed Out on AveXis (AVXS) But Well-Positioned for Substantial Acquisition - RBC
-
Pre-Open Movers 01/25: (DLB) (VAR) (MKC) Higher; (CFMS) (OCUL) (NWL) Lower (more...)
-
RBC Capital Starts Biogen (BIIB) at Sector Perform
-
Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference
-
Trump's corporate tax holiday could spur pharma M&A
-
Pre-Open Stock Movers 09/28: (SEED) (AVXL) (ATHX) Higher; (GALT) (TPX) (SONC) Lower (more...)
-
Allergan pays top dollar for 'stepping stones' from neurology to dermatology
-
Perrigo explores sale of royalties of drug Tysabri: sources
-
Biogen (BIIB) Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee
-
U.S. biotech stocks win back investors in big July run
-
Notable Analyst Rating Changes 6/29: (DYN) (CNC) (DAR) Upgraded; (HAR) (ESPR) (ZION) Downgraded
-
Biotech Seen Grinding Higher, Says RBC Capital (IBB)
-
RBC Comments on Bull/Bear Case on Biogen (BIIB) Following Q3 Results